LivaNova Manufacturing Update

Industry Resources

© 2020 LivaNova, Inc. All Rights Reserved. 


As a healthcare company committed to improving the lives of patients around the world, LivaNova is closely monitoring the coronavirus situation and is reacting accordingly as the issues evolve. 

Last Updated:

Society of Thoracic

Contact Us For More Information

100 Cyberonics Blvd Houston, TX 77058

American College of Cardiology

LivaNova Resources

Customer LetterTandemLifePress Release

Thank you to Healthcare Professionals
who are working tirelessly to fight COVID-19 in our communities.

LivaNova Permitted to Modify Cardiopulmonary Products Indications for Use to Include ECMO Therapy Beyond Six Hours to Address COVID-19

COVID-19 UPDATES:The U.S. Food and Drug Administration (FDA) issued guidance on April 6, 2020 to temporarily expand the availability of devices used in extracorporeal membrane oxygenation (ECMO) therapy to address the novel coronavirus (COVID-19) public health emergency. As a result of the guidance, cardiopulmonary devices, including select devices from LivaNova, are now temporarily indicated for ECMO therapy greater than 6 hours. To read the full announcement, click here. 

Click Here For The Latest UpdatesJoint PerfusionS5 Heart-Lung MachineCP5 Centrifugal Pump DriverRevolution Centrifugal PumpInspire Family of OxygenatorsEOS PMP Oxygenator

Supplement Letters for LivaNova Devices

EasyFlow CannulaRAP Cannula
Stay Connected